Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019

Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019

View PDF

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

View Poster

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

View PDF

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

Crescendo Biologics announces early licensing by Takeda
of first oncology-targeted Humabody®

View PDF